^
Association details:
| Biomarker: | MET Y1003C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers
Published date:
08/18/2020
Excerpt:
Among evaluable patients harboring MET-ex14 alterations, longer progression-free survival (PFS) was observed with crizotinib than with chemotherapy (8.5 months versus 4.0 months, p = 0.041), but there was no difference in overall survival (OS, 11.3 months versus 12.0 months, p = 0.66)... Concurrent MET amplification results in a shorter PFS (4.2 months versus 8.5 months, p = 0.029) but a comparable OS (7.8 months versus 14.0 months, p = 0.12)...A novel MET Y1003C mutation was detected and demonstrated a clinical response to crizotinib.
DOI:
https://doi.org/10.1016/j.lungcan.2020.08.009
